Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to 28%.

A once-weekly triple receptor agonist conferred up to 28.3% weight loss at 80 weeks for adults with overweight or obesity, according to topline results from a phase 3 trial. As…

The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.

Eli Lilly's retatrutide shows promise, helping obesity patients lose over 28% of their weight in a key trial.

A new weight loss drug from Eli Lilly made patients lose 28% of their body weight on average, levels achieved only by surgery before.

Eli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This once-weekly injection targets multiple…